The theoretical construct of what happens when drug patents expire is simple and appealing (to consumers, anyway). A name brand drug patent expires, generics are waiting in the wings to…
The post What Happens When a Drug Patent Expires? appeared first …
This paper was originally published by Harinder Singh Chahal, Jeffrey S Murray, Martin Shimer, Peter Capella, Ryan Presto, Mary Lou Valdez, and Peter G Lurie in Journal of the International AIDS…
The post The US Food and Drug Administration’s tentative…
This paper was originally published by J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski in Front. Oncol., 14 November 2017 under a …
The post Giving Drugs a Second Chance: Overc…
Litigation related to drug patents, whether it be direct patent challenges, contract disputes, or other cases, can provide direct intelligence (through disclosures of competitive intelligence) or indirect intelligence through exposure…
The post Improve…
Pharmacists, as the interface between the general public and prescription drug manufacturers, can sometimes feel as if they’re treading a fine line between fulfilling their obligations to pharmaceutical companies and…
The post How Pharmacists Are Trapp…
Which Company Will be the First to Launch a Generic Drug? There are many reasons to find out which companies will be first to launch generic drugs. Payers need to…
The post How to Use Tentative Drug Approvals to Anticipate Generic Entry appeared first …
Which Company Will be the First to Launch a Generic Drug? There are many reasons to find out which companies will be first to launch generic drugs. Payers need to…
The post How to Use Tentative Drug Approvals to Anticipate Generic Entry appeared first …
This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2…
This paper was originally published by Martin Schiestl, Markus Zabransky, and Fritz Sörgel in Drug Des Devel Ther. 2017; 11: 1509–1515 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract…
The post Ten years of biosi…
What can we build for you? Do you have special business intelligence needs? Let us apply our industry expertise and the strength of the DrugPatentWatch platform to develop a solution…
The post Make better decisions with advanced biopharmaceutical busin…